Page 17 - Trial Data News Today : Breaking News, Live Updates & Top Stories | Vimarsana

5 to 11, so still important to emphasize adults getting vaccinated. we have room to go on that front. >> what information data research? 5 to 11 is a very young age. >> it is a young age. luckily we have a road map not with covid but other vaccines in children. this is a deescalation trial, the same vaccine any adult who gets pfizer would get but lower doses, two doses three weeks apart but looking in the trial data for safety, looking at all the safety issues that the adults and teens looked at and once the data shows as you mentioned, they looked for what we would call noninferiority, meanin...

A snmall group staged protests t the hospital including andrea herself. one of her specific health concerns, blood clots. if you were my patient, let's say we were having this conversation in a patient room instead, i would tell you, look, i hear your concern about clotting, but if you have a clotting disorder, you should get the vaccine because you at increase risk of clotting if you got the disease. >> we know that very well with this pandemic, this vaccine this virus, the science is constantly changing and i understand that science is changing as we find out more things. >> but i think with...

But hasn't actually filed that emergency authorization, but it's coming soon, and then it will take several weeks after that. remember, these advisory committees that have been debating boosters will be able to convene and meet. 5 to 11, i would optimistically say november, 2 to 5 as the ceo mentioned, that trial data is ongoing, being evaluated. jose, if the data is compelling, the data safety and monitoring board can signal, yes, we think your data is good enough to start the process and we hope that will happen in the next month or two. that's why we have to kind of expect that for 2 to 5 i...

Now starting the process of terminating 593 employees who didn't get the shots. those workers can still save their jobs if they opt to get vaccinated in the coming days. meanwhile, pfizer took a major step toward receiving approval of its covid vaccine for children, ages 5 to 11, submitting trial data to the fda for review after recently determining the vaccine is safe and well tolerated. nbc news correspondent gabe gutierrez has the latest. >> reporter: with millions of children now back in classrooms, izer submitted phase 3 data to the fda for vaccines 5 to 11-year-olds, crucial step to au...

Announcer: this is “nbc nightly news" with lester holt >> good evening, everyone pfizer today took a major step toward approval of its covid vaccine for childrens 5 to 11. submitting trial data to the fda for review after recently determining it is safe and well tolerated a vaccine suitable for younger children is a major missing piece in the country's effort to turn back the pandemic especially with parents and many schools navigating infection outbreaks. but also today, the biden administration saying those pfizer booster shots fo certain americans are taking off a million shot appointment...